An Open-Label, Single-Arm, Multicenter Study To Assess The Safety Of Vemurafenib In Patients With Braf V600 Mutation Positive Metastatic Melanoma In South Africa.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Roche
- 04 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
- 04 Nov 2016 Planned primary completion date changed from 1 Jun 2015 to 1 Dec 2018.
- 11 May 2015 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.